COMP <GO>
NBIX vs HALO // FORWARD P/E MULTIPLE
Neurocrine Biosciences Inc. (NASDAQ) VS. Halozyme Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NBIX 7
— HALO 6
▲ FORWARD P/E MULTIPLE LEADER: NBIX
LAST: $145.35 (-0.51%) • MKT CAP: $14.85B
forward-pe
26.1x
LAST: $128.95 (-1.50%) • MKT CAP: $14.86B
forward-pe
39.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. HALO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | HALO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.60% | +12.40 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 18.00% | -2.30 | HALO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 35.6x | -12.80 | NBIX | /valuation <GO> |
| Free Cash Flow Yield | 5.03% | 4.33% | +0.70 | NBIX | /fcf-yield <GO> |
| Operating Margin | 21.60% | 33.60% | -12.00 | HALO | /operating-margins <GO> |
| Net Profit Margin | 16.70% | 22.70% | -6.00 | HALO | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 37.60% | -16.20 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 5.11 | +3.02 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.2 | 77.8 | -22.60 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.88 | +0.25 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.1x | 39.5x | -13.40 | NBIX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.85B | $14.86B | -$7.1M | HALO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | HALO REV | NBIX GROSS % | HALO GROSS % | NBIX FCF | HALO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $1.40B | 98.2% | 83.6% | $748.7M | $644.6M |
| FY 2024 | $2.36B | $1.02B | 98.6% | 84.3% | $557.2M | $468.4M |
| FY 2023 | $1.89B | $829.3M | — | — | $305.0M | $351.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
HALO // BETA 0.88